Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C18H20N2O2 |
| Molecular Weight | 296.3636 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCC2=C3C1CC=C(N3C4=C2C=CC=C4)C(=O)OC
InChI
InChIKey=JWOSSISWAJNJIA-UHFFFAOYSA-N
InChI=1S/C18H20N2O2/c1-3-19-11-10-13-12-6-4-5-7-14(12)20-16(18(21)22-2)9-8-15(19)17(13)20/h4-7,9,15H,3,8,10-11H2,1-2H3
| Molecular Formula | C18H20N2O2 |
| Molecular Weight | 296.3636 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Vinconate possesses both encephalotropic and psychotropic properties. Animal experiments have shown that this compound could induce the facilitation of phosphatidylinositide (PI) turnover via the stimulation of muscarinic acetylcholine receptors. In addition, vinconate could lead to the direct activations of PIP2-specific and cytosolic phospholipase C. The drug was on the stage of preregistration for the treatment of cognition disorders in Japan. However, information about the further fate of this drug is not available.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Susceptibility to Calcium Dysregulation during Brain Aging. | 2009 |
|
| Effects of vinconate on scopolamine-induced memory impairment in rhesus monkeys. | 2003-02 |
|
| Vinconate, a cognitive enhancer, and PI turnover-phospholipase C systems in the brain. | 1997-02 |
|
| Classification and determination of pharmacodynamics of a new antihypoxidotic drug, vinconate, by pharmaco-EEG and psychometry. | 1984-07 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6476974
In a double-blind, placebo-controlled study the encephalotropic and psychotropic properties of both orally and intravenously administered doses of vinconate. They received at weekly intervals randomized single oral doses of placebo, 40 mg, 80 mg and 160 mg vinconate orally as well as placebo and 30 mg vinconate intravenously
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:14:59 GMT 2025
by
admin
on
Mon Mar 31 23:14:59 GMT 2025
|
| Record UNII |
USR9X88XYU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
USR9X88XYU
Created by
admin on Mon Mar 31 23:14:59 GMT 2025 , Edited by admin on Mon Mar 31 23:14:59 GMT 2025
|
PRIMARY | |||
|
753420-20-1
Created by
admin on Mon Mar 31 23:14:59 GMT 2025 , Edited by admin on Mon Mar 31 23:14:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |